Renal vulnerability to drug toxicity

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 7, 2009, Pages 1275-1283

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANALGESIC AGENT; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BEVACIZUMAB; CHOLINERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; CYCLOOXYGENASE 2 INHIBITOR; GEMCITABINE; GERMANIUM; HEAVY METAL; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PERGOLIDE; RAPAMYCIN; SILICON; SOLVENT; SULFADIAZINE; TENOFOVIR; UNINDEXED DRUG; ZOLEDRONIC ACID;

BLADDER DYSFUNCTION; CHRONIC KIDNEY DISEASE; DRUG EXPOSURE; ENVIRONMENTAL EXPOSURE; FOCAL GLOMERULOSCLEROSIS; HEMODYNAMICS; HIGH RISK POPULATION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LIVER CIRRHOSIS; LOSS OF FUNCTION MUTATION; MEMBRANOUS GLOMERULONEPHRITIS; METABOLIC DISORDER; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PROTEINURIA; RETROPERITONEAL DISEASE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STONE FORMATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; KIDNEY DISEASE;

DRUG TOXICITY; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 70349303831     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02050309     Document Type: Review

References (52)

1. Schetz M, Dasta J, Goldstein S, Golper T: Drug-induced acute kidney injury. Curr Opin Crit Care 11: 555-565, 2005
2. Elseviers MM, DeBroe ME: Analgesic nephropathy: Is it caused by multi-analgesic abuse or single substance use? Drug Saf 20: 15-24, 1999
3. Izzedine H, Launay-Vacher V, Deray G: Antiviral druginduced nephrotoxicity. Am J Kidney Dis 45: 804-817, 2005
4. Kintzel PE: Anticancer drug-induced kidney disorders. Drug Saf 24: 19-38, 2001
5. Perazella MA: Drug-induced nephropathy: An update. Expert Opin Drug Saf 4: 689-706, 2005
6. Gambaro G, Perazella MA: Adverse renal effects of antiinflammatory agents: Evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 253: 643-652, 2003
7. Rougier F, Ducher M, Maurin M, Corvaisier S, Claude D, Jeliffe R, Maire P: Aminoglycoside dosages and nephrotoxicity. Clin Pharmacokinet 42: 493-500, 2003
8. Lamieire NH, Flombaum CD, Moreau D, Ronco C: Acute renal failure in cancer patients. Ann of Med 37: 13-25, 2005
9. Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A, Foraccio A, Montorfano M, Carlino M, Condorelli G, Ricciardelli B: Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: Impact of N-acetylcysteine. Kidney Int 68: 2250-2255, 2005
10. Ergun I, Kenan K, Uruc I, Ekmekci Y, Canbakan B, Erden I, Karatan O: The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21: 697-700, 2006
11. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL: Herbs and the kidney. Am J Kidney Dis 44(1): 1-11, 2004
12. Blowey DL: Nephrotoxicity of over-the-counter analgesics, natural medicines, and illicit drugs. Adolesc Med Clin 16: 31-43, 2005
13. Wang IJ, Chen PC, Hwang KC: Melamine and nephrolithiasis in children in Taiwan. N Engl J Med 12; 360(11): 1157-1158, 2009
14. Van Vleet TR, Schnellmann RG: Toxic nephropathy: Environmental chemicals. Semin Nephrol 23: 500-508, 2003
15. Brewster UC, Perazella MA: A review of chronic lead intoxication: An unrecognized cause of chronic kidney disease. Am J Med Sci 327(6): 341-347, 2004
16. Yu CC, Lin JL, Lin-Tan DT: Environmental exposure to lead and progression of chronic renal diseases: A four-year prospective longitudinal study. J Am Soc Nephrol 15(4): 1016-1022, 2004
17. Jerkic M, Vojvodic S, Lopez-Novoa JM: The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. The role of increased vasoconstriction. Int Urol Nephrol 32(4): 539-547, 2001
18. Evenepoel P: Acute toxic renal failure. Best Prac & Res Clin Anaesthesiol 18: 37-52, 2004
19. Singh NP, Ganguli A, Prakash A: Drug-induced kidney diseases. JAPI 51: 970-979, 2003
20. Guo X, Nzerue C: How to prevent, recognize, and treat drug-induced nephropathy. Cleve Clin J Med 69(4): 289-297, 2002
21. Wyatt CM, Arons RR, Klotman PE, Klotman ME: Acute renal failure in hospitalized patients with HIV: Risk factors and impact on in-hospital mortality. AIDS 20: 561-565, 2006
22. Lucena MI, Andrade RJ, Cabello MR, Hidalgo R, Gonzalez-Correa JA, Sanchez de la Cuesta F: Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol 22(2): 189-196, 1995
23. Markowitz GS, Perazella MA: Drug-induced renal failure: A focus on tubulointerstitial disease. Clin Chimica Acta 351: 31-47, 2005
24. Perazella MA, Brown E: Electrolyte and acid-base disorders associated with AIDS: An etiologic review. J Gen Intern Med 9(4): 232-236, 1994
25. Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G: Ciprofloxacin crystal nephropathy. Am J Kidney Dis 50(2): 330-335, 2007
26. Vega D, Maalouf NM, Sakhaee K: Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf 6(5): 547-557, 2007
27. Wroe S: Zonisamide and renal calculi in patients with epilepsy: How big an issue? Curr Med Res Opin 23(8): 1765-1773, 2007
28. Harty L, Johnson K, Power A: Race and ethnicity in the era of emerging pharmacogenomics. J Clin Pharmacol 46: 405-407, 2006
29. Ciarimboli G, Koepsell H, Iordanova M, Gorboulev V, Durner B, Lang D, Edemir B, Schroter R, Van Le T, Schlatter E: Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol 16:1562-1570, 2005
30. Ulrich CM, Bigler J, Potter JD: Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews 6: 130-140, 2006
31. Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ.: Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol 17: 2919 -2927, 2006
32. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray AG: Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194(11): 1481-1491, 2006
33. Cummings BS, Schnellmann RG: Pathophysiology of nephrotoxic cell injury. In Diseases of the Kidney and Urogenital Tract, edited by Schrier RW, Philadelphia PA, Lippincott Williams & Wilkinson, 2001, pp 1071-1136
34. Kaloyanides GJ, Bosmans J-L, DeBroe ME: Antibiotic and Immunosuppression-related renal failure. In Schrier RW (ed): Diseases of the Kidney and Urogenital Tract, edited by Schrier RW, Philadelphia PA, Lippincott Williams & Wilkinson, 2001, pp 1137-1174
35. Aleksa K, Matsell D, Krausz K, Gelboin H, Ito S, Koren G: Cytochrome P450 3A and 2B6 in the developing kidney: Implications for ifosfamide nephrotoxicity. Pediatr Nephrol 20: 872-885, 2005
36. Nagai J, Takano M: Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokin 19: 59-70, 2004
37. Fanos V, Cataldi L: Renal transport of antibiotics and nephrotoxicity: A review. J Chemother 13: 461-472, 2001
38. Orbach H, Tishler M, Shoenfeld Y: Intravenous immuno-globulin and the kidney-A two-edged sword. Semin Arthritis Rheum 34: 593-601, 2004
39. Enomoto A, Endou H: Roles of organic anion transporters (OATS) and urate transporter (URAT1) in the pathophysiology of human disease. Clin Exp Nephrol 9: 195-205, 2005
40. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, Haier J, Jaehde U, Zisowsky J, Schlatter E: Cisplatin nephrotoxicity is critically medicated via the human organic cation transporter 2. Am J Pathol 167: 1477-1484, 2005
41. Lang F: Regulating renal drug elimination. J Am Soc Nephrol 16: 1535-1536, 2005
42. Alexander BD, Wingard JR: Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis. 40 Suppl 6: S414-S421, 2005
43. Falagas ME, Kasiakou SF: Nephrotoxicity of intravenous colistin: A prospective evaluation. Crit Care 10:R27 1-13, 2006
44. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhaksrishnan, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64: 281-289, 2003
45. Yang JC, Hayworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003
46. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11): 1129-1136, 2008
47. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605-12608, 2003
48. Gurevich F, Perazella MA: Renal effects of anti-angiogenesis therapy: Update for the Internist Am J Med. 122: 322-328, 2009
49. Bennett WM, Henrich WL, Stoff JS: The renal effects of nonsteroidal anti-inflammatory drugs: Summary and recommendations. Am J Kidney Dis 28(1 Suppl 1): S56-S62, 1996
50. Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R: Drug-induced urinary retention: Incidence, management and prevention. Drug Saf 31: 373-388, 2008
51. Brewster UC, Perazella MA: Proton pump inhibitors and the kidney: Critical review. Clin Nephrol 68(2): 65-72, 2007
52. Letavernier E, Bruneval B, Mandet C, Van Huyen JPD, Péraldi MN, Helal I, Noël LH, Legendre C: High sirolimus levels may induce focal segmental glomerulosclerosis De Novo. Clin J Am Soc Nephrol 2: 326-333, 2007